الفهرس 
Surgical management of female breast cancer patients after neoadjuvant systemic therapy for Invasive ductal versus invasive lobular carcinoma
AbstractOnly 14 pages are availabe for public view
 |  | from | 177 |  |  |
| | | from | 177 | | |
Abstract
Neoadjuvant chemotherapy (NAC) is increasingly used in the treatment of patients with breast cancer. The NAC approach has several objectives, including downsizing of irresectable locally advanced breast cancer into operable disease. However, preoperative chemotherapy is also a possibility for patients with operable tumors leading to smaller breast resection and better cosmetic outcome. Furthermore, it allows in vivo monitoring of the tumor{u2019}s chemosensitivity and also gives the opportunity for downstaging of disease in the axilla, obviating the need for axillary treatment in some patients. However, from a surgical point of view, the most important objective of NAC is to increase the possibility that conservative breast surgery can be performed. Invasive lobular carcinoma (ILC) is the second most common type of breast cancer, constituting 5-15 % of all histologic types of breast cancer. Due to its specific clinical, biologic, and prognostic features, ILC often is considered to be a distinct clinical entity different from invasive ductal carcinoma. Invasive lobular carcinoma has been reported to be less responsive to neoadjuvant chemotherapy than invasive ductal carcinoma. This study will compare the impact of neoadjuvant systemic therapy on the patients with invasive ductal versus invasive lobular breast cancer in form of difference in response and surgical management